© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
Converge Coverage
SGLT-2 inhibitors promising for heart failure prevention, not treatment
EXPERT ANALYSIS FROM WCIRDC 2018
Related Articles
![1]()
SGLT2 inhibitor use tied to fewer atrial arrhythmias
January 12, 2019
A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.
![1]()
Empagliflozin a winner in challenging arena of stabilized acute HF
January 12, 2019
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.
![1]()
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
January 12, 2019
A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.
Some diabetes drugs may lower risk of severe COVID-19 outcomes
January 12, 2019
Glucose-regulating medications may improve outcomes in COVID-19 patients with type 2 diabetes, a multinational retrospective cohort study suggests.
